Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity

Inclusion Criteria

• •1. Patient aged 18 or over
• •2. Patients with AML de novo or secondary to myelodysplastic syndrome or therapy-related AML except acute myeloid leukemia (AML3)
• •3. Patient hospitalized for the treatment of leukemia (induction chemotherapy or consolidation)
• •4. General state retained (ECOG performance scale ≤ 3)
• •5. alanine aminotransferase aspartate transaminase (ASAT) and alanine aminotransferase (ALAT) ≤ 2.5 times the upper limit of normal (ULN), total bilirubin ≤ 2 times the ULN, creatinine \<150 μmol / L unless these biological abnormalities are related to leukemia
• •6. Patients affiliated or beneficiaries of a social security scheme (Social Security or Universal Medical Coverage)
• •7. Having read and understood the information sheet and signed the informed consent